Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Arash Pakseresht"'
Autor:
Sean Wharton, Christiane L. Haase, Elham Kamran, Aiden Liu, Johanna Mancini, Drew Neish, Arash Pakseresht, G Sarah Power, Rebecca A. G. Christensen
Publikováno v:
Obesity Science & Practice, Vol 6, Iss 4, Pp 439-444 (2020)
Summary Objective Liraglutide 3.0 mg is associated with clinically significant weight loss in clinical trials, but real‐world data are lacking. In this analysis, weight loss and persistence outcomes with liraglutide 3.0 mg were assessed across obes
Externí odkaz:
https://doaj.org/article/40a7c9a759e64874b3401670449e4ac1
Autor:
Sean Wharton, Christiane L Haase, Elham Kamran, Aiden Liu, Johanna Mancini, Drew Neish, Arash Pakseresht, G Sarah Power, Rebecca AG Christensen
Publikováno v:
Obesity Science & Practice, Vol 6, Iss 4, Pp 382-389 (2020)
Summary Objective Weight management medications can significantly increase patients' chances of achieving a clinically meaningful weight loss if patients persist with treatment. This retrospective observational study of de‐identified medical record
Externí odkaz:
https://doaj.org/article/b1e41395ee644095b92b842ca20e8a0b
Autor:
G Sarah Power, Aiden Liu, Elham Kamran, Arash Pakseresht, Sean Wharton, Drew Neish, Rebecca A. G. Christensen, Christiane L Haase, Johanna Mancini
Publikováno v:
Obesity Science & Practice, Vol 6, Iss 4, Pp 439-444 (2020)
Obesity Science & Practice
Obesity Science & Practice
Summary Objective Liraglutide 3.0 mg is associated with clinically significant weight loss in clinical trials, but real‐world data are lacking. In this analysis, weight loss and persistence outcomes with liraglutide 3.0 mg were assessed across obes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04edfd3aa95e3512539f98a383874289
https://doi.org/10.1002/osp4.420
https://doi.org/10.1002/osp4.420
Autor:
Iichiro Shimomura, Ole K. Jeppesen, Adie Viljoen, Louise Færch, Arash Pakseresht, Ildiko Lingvay, Sue D. Pedersen, Leigh Perreault, Melanie J. Davies, René Gollan, Julio Rosenstock, Thomas A. Wadden
Publikováno v:
Adipositas-Kongress 2021 – 37. Jahrestagung der Deutschen Adipositas-Gesellschaft e.V..
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f573cc71b5ce8f12da85da3d6c95853f
https://doi.org/10.1055/s-0041-1735690
https://doi.org/10.1055/s-0041-1735690
Autor:
Julio Rosenstock, Iichiro Shimomura, Adie Viljoen, Thomas A. Wadden, Ole Jeppesen, Leigh Perreault, Ildiko Lingvay, Louise Færch, Melanie J. Davies, Sue Pedersen, Arash Pakseresht
Publikováno v:
Diabetes. 70
The STEP 2 trial showed mean weight loss of 9.6% with semaglutide 2.4 mg vs. 7.0% with semaglutide 1.0 mg vs. 3.4% with placebo (PBO; both p Disclosure L. Perreault: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Novo Nordisk, Cons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b258ffdc9100835a73209e77dba14db
https://doi.org/10.2337/db21-82-or
https://doi.org/10.2337/db21-82-or
Autor:
Ole K. Jeppesen, Louise Færch, Thomas A. Wadden, Adie Viljoen, Melanie J. Davies, Julio Rosenstock, Ildiko Lingvay, Arash Pakseresht, Leigh Perreault, Iichiro Shimomura, Sue D. Pedersen
Publikováno v:
Lancet (London, England). 397(10278)
Summary Background This trial assessed the efficacy and safety of the GLP-1 analogue once a week subcutaneous semaglutide 2·4 mg versus semaglutide 1·0 mg (the dose approved for diabetes treatment) and placebo for weight management in adults with o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea13642496cae902a71ce7170cbbf2e4
https://pubmed.ncbi.nlm.nih.gov/33667415
https://pubmed.ncbi.nlm.nih.gov/33667415
Autor:
Leigh Perreault, Julio Rosenstock, Ildiko Lingvay, Melanie J. Davies, Sue D. Pedersen, Arash Pakseresht, Ole K. Jeppesen, Louise Færch, Adie Viljoen, Thomas A. Wadden, Iichiro Shimomura
Publikováno v:
Journal of the Endocrine Society
Background: In people with overweight/obesity and type 2 diabetes (T2D), achievement of weight loss can be a challenge. STEP 2 investigated the efficacy and safety of semaglutide 2.4 mg for weight management in adults with overweight/obesity and T2D.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::305d8750004cb45f45b5dcf5004bc7d0
https://doi.org/10.1210/jendso/bvab048.019
https://doi.org/10.1210/jendso/bvab048.019
Autor:
Christiane L Haase, Sean Wharton, Johanna Mancini, Arash Pakseresht, Aiden Liu, Elham Kamran, Drew Neish, Rebecca A. G. Christensen, G Sarah Power
Publikováno v:
Obesity Science & Practice
Obesity Science & Practice, Vol 6, Iss 4, Pp 382-389 (2020)
Obesity Science & Practice, Vol 6, Iss 4, Pp 382-389 (2020)
Summary Objective Weight management medications can significantly increase patients' chances of achieving a clinically meaningful weight loss if patients persist with treatment. This retrospective observational study of de‐identified medical record
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18a21788432296451d8b0832eb3f1bb3
https://pubmed.ncbi.nlm.nih.gov/32874673
https://pubmed.ncbi.nlm.nih.gov/32874673
Autor:
Noel MacKay, Marie-France Langlois, Diana Lawlor, André Bélanger, Arya M. Sharma, Suzanne Lepage, David Macklin, Veronica Carson, Aiden Liu, Ximena Ramos Salas, Michael Vallis, Sue Pedersen, Arash Pakseresht, Jodi Krah
Publikováno v:
Clinical Obesity
Summary Obesity is a chronic disease with a significant and growing impact on Canadians. The “Awareness, Care and Treatment In Obesity MaNagement” (ACTION) Study investigated perceptions, attitudes and perceived barriers to obesity management amo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f0d0cb17919c1bc2896f2de1f3feef1
http://europepmc.org/articles/PMC6771494
http://europepmc.org/articles/PMC6771494
Autor:
Arash Pakseresht, Emil Nørtoft, Christiane L Haase, Sean Wharton, Rebecca A. G. Christensen, Johanna Mancini, Aiden Liu, Sarah VanderLelie, G Sarah Power
Publikováno v:
Obesity (Silver Spring, Md.)
Objective Real‐world clinical effectiveness of liraglutide 3.0 mg, in combination with diet and exercise, was investigated 4 and 6 months post initiation. Changes in absolute and percent body weight were examined from baseline. Methods A cohort of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb1f86f10159283fd5a3e349c754276d
https://pubmed.ncbi.nlm.nih.gov/31545004
https://pubmed.ncbi.nlm.nih.gov/31545004